Proportion of patients with AE grade 3 and 4 during cycles 1 to 12 and GVHD and secondary malignancies during follow-up
| . | Grade 3 . | Grade 4 . |
|---|---|---|
| Any grade 3/4 AE, % | 53 | 23 |
| Blood/bone marrow, % | 27 | 17 |
| Metabolic/laboratory, % | 23 | 7 |
| Infection, % | 17 | — |
| GVHD, patients (%) | 16 (53) | — |
| Acute GVHD ≥ grade 2, patients (%) | 11 (37) | — |
| Skin/skin + liver/liver/gut, patients | 5/3/2/1 | — |
| Grade 2/3/4, patients | 5/6/0 | — |
| Classic/late onset, patients | 4/7 | — |
| Chronic extensive GVHD, patients (%) | 5 (17) | — |
| Secondary malignancy, patients (%) | — | 2 (6.7)* |
| . | Grade 3 . | Grade 4 . |
|---|---|---|
| Any grade 3/4 AE, % | 53 | 23 |
| Blood/bone marrow, % | 27 | 17 |
| Metabolic/laboratory, % | 23 | 7 |
| Infection, % | 17 | — |
| GVHD, patients (%) | 16 (53) | — |
| Acute GVHD ≥ grade 2, patients (%) | 11 (37) | — |
| Skin/skin + liver/liver/gut, patients | 5/3/2/1 | — |
| Grade 2/3/4, patients | 5/6/0 | — |
| Classic/late onset, patients | 4/7 | — |
| Chronic extensive GVHD, patients (%) | 5 (17) | — |
| Secondary malignancy, patients (%) | — | 2 (6.7)* |
— indicates none (ie, no patients).
Two solid tumors were reported during follow-up: one ovarian tumor and one breast carcinoma.